You-Ping Chan

THERMOSTABLE FORMULATION OF A21G HUMAN INSULIN

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID

PHARMACEUTICAL COMPOSITION IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION INCLUDING AT LEAST A RAPID ACTING INSULIN ANALOG AND A GLUCAGON SUPPRESSOR WITH PRANDIAL ACTION

PHARMACEUTICAL COMPOSITION IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION INCLUDING AT LEAST A RAPID-ACTING INSULIN ANALOG AND A GLUCAGON SUPPRESSOR WITH PRANDIAL ACTION

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID

INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST A BASAL INSULIN WHICH PI IS COMPRISED BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID

THERMOSTABLE FORMULATION OF A21G HUMAN INSULIN

Injectable pH 7 solution comprising at least one basal insulin having a pI from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

Compositions in the form of an injectable aqueous solution including at least human insulin A21G and a glucagon suppressor with prandial action

INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE PI OF WHICH IS FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid

Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid

Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid

Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid

INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

Compositions in the form of an injectable aqueous solution including at least human insulin A21G and a glucagon suppressor with prandial action

Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations

MODIFIED-RELEASE MICROPARTICLES BASED ON AMPHIPHILIC COPOLYMER AND ON ACTIVE PRINCIPLE(S) AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM

IFN-beta compositions, preparation methods and uses thereof

COMPOSITION FOR THE CONTROLLED RELEASE OF BUPRENORPHINE

COMPOSITION COMPRISING INTERFERON ALPHA

Amphiphilic polymer functionalized by methionine

Polymer of acrylic or methacrylic type comprising alpha-tocopherol grafts

COPOLYHYDROXYALKYLGLUTAMINES FUNCTIONALISED WITH HYDROPHOBIC GROUPS, AND USES THEREOF, ESPECIALLY IN THERAPEUTICS

Composition comprising an active agent with low aqueous solubility

POLYAMINOACIDS FUNCTIONALIZED WTIH ALPHA-TOCOPHEROL, AND USES THEREOF, ESPECIALLY THERAPEUTIC USES

Polyglutamic acids functionalized by cationic groups and hydrophobic groups and applications thereof, in particular therapeutic applications thereof

Modified-release particles of polyelectrolytes and pharmaceutical formulations thereof

Self-precipitating pharmaceutical formulations for the modified release of an active principle